WallStSmart

Chimerix Inc (CMRX)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 285949% more annual revenue ($606.42M vs $212,000). CMRX leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).

CMRX

Avoid

29

out of 100

Grade: F

Growth: 4.0Profit: 2.5Value: 5.0Quality: 5.0

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CMRX0 strengths · Avg: 0/10

No standout strengths identified

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

CMRX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$801.08M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-56.2%2/10

ROE of -56.2% — below average capital efficiency

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : CMRX

Revenue growth of 13.3% demonstrates continued momentum.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : CMRX

The primary concerns for CMRX are EPS Growth, Market Cap, Profit Margin.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

CMRX profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

CMRX is growing revenue faster at 13.3% — sustainability is the question.

CMRX generates stronger free cash flow (-19M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 29/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Chimerix Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Chimerix, Inc., a developing-stage biopharmaceutical company, focuses on accelerating the advancement of various drugs that impact the lives of patients living with cancer and other serious diseases. The company is headquartered in Durham, North Carolina.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?